Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01044758 · ClinicalTrials.gov registry record · Phase 2
Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT01044758: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT01044758 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01044758, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD).
Primary Outcome
Measurement of average brain activity in the dentate gyrus / CA3 subregion of the hippocampus measured with BOLD functional MRI in patients with mild cognitive impairment on placebo and on drug compared to average brain activity in this brain area in control subjects.
Interventions
- DRUG Placebo
- DRUG Levetiracetam 62.5mg
- DRUG Levetiracetam 125mg
- DRUG Levetiracetam 250mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01044758 record still lists
NCT01044758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01044758 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01044758 about?
NCT01044758 is a clinical study titled "Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)". This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD).
What is the current status of trial NCT01044758?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2009-12. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01044758?
The interventions under investigation include: Placebo (DRUG), Levetiracetam 62.5mg (DRUG), Levetiracetam 125mg (DRUG), Levetiracetam 250mg (DRUG).
Who is sponsoring clinical trial NCT01044758?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01044758's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia